scholarly journals Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

2018 ◽  
Vol 6 (9) ◽  
pp. 699-706 ◽  
Author(s):  
Kathryn Schnippel ◽  
Norbert Ndjeka ◽  
Gary Maartens ◽  
Graeme Meintjes ◽  
Iqbal Master ◽  
...  
Keyword(s):  
Cohort Study ◽  
South African ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
African Patients

Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study

The Lancet ◽  
2008 ◽  
Vol 372 (9647) ◽  
pp. 1403-1409 ◽  
Author(s):  
Salmaan Keshavjee ◽  
Irina Y Gelmanova ◽  
Paul E Farmer ◽  
Sergey P Mishustin ◽  
Aivar K Strelis ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant

scholarly journals Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e047023
Author(s):  
Weixi Jiang ◽  
Ying Peng ◽  
Xiaomeng Wang ◽  
Chris Elbers ◽  
Shenglan Tang ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Zhejiang Province ◽  
Vulnerable Groups ◽  
Drug Resistant ◽  
Policy Changes ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Complete Treatment

ObjectivesTo examine changes in the screening, diagnosis, treatment and management of drug-resistant tuberculosis (DRTB) patients, and investigate the impacts of DRTB-related policies on patients of different demographic and socioeconomic characteristics.DesignA retrospective cohort study using registry data, plus a survey on DRTB-related policies.SettingAll prefecture-level Centres for Disease Control in Zhejiang Province, China.Main outcome measuresAlongside the care cascade, we examined: (1) reported number of presumptive DRTB patients; (2) percentage of presumptive patients with drug susceptibility testing (DST) records; (3) percentage of DRTB/rifampicin-resistant (RR) patients registered; (4) percentage of RR/multidrug-resistant TB (MDRTB) patients that received anti-DRTB treatment; and (5) percentage of RR/MDRTB patients cured/completed treatment among those treated. Multivariate logistic regressions were conducted to explore the impacts of DRTB policies after adjusting for other factors.ResultsThe number of reported presumptive DRTB patients and the percentage with DST records largely increased during 2015–2018, and the percentage of registered patients who received anti-DRTB treatment also increased from 59.0% to 86.5%. Patients under the policies of equipping GeneXpert plus expanded criteria for DST had a higher likelihood of being registered compared with no GeneXpert (adjusted OR (aOR)=2.57, 95% CI: 1.20 to 5.51), while for treatment initiation the association was only significant when further expanding the registration criteria (aOR=2.38, 95% CI: 1.19 to 4.79). Patients with registered residence inside Zhejiang were more likely to be registered (aOR=1.96, 95% CI: 1.52 to 2.52), treated (aOR=3.83, 95% CI: 2.78 to 5.28) and complete treatment (aOR=1.92, 95% CI: 1.03 to 3.59) compared with those outside.ConclusionThe policy changes on DST and registration have effectively improved DRTB case finding and care. Nevertheless, challenges remain in servicing vulnerable groups such as migrants and improving equity in the access to TB care. Future policies should provide comprehensive support for migrants to complete treatment at their current place of residence.

Sign in / Sign up

Export Citation Format

Share Document